Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check23 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study objectives and inclusion criteria for a clinical trial related to Non-Small-Cell Lung Carcinoma, while adding a new identifier and revision number.SummaryDifference34%
Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.